Related references
Note: Only part of the references are listed.Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open
Bruce E. Sands et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis
Loriane Lair-Mehiri et al.
DIGESTIVE AND LIVER DISEASE (2020)
Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice
Javier P. Gisbert et al.
JOURNAL OF CROHNS & COLITIS (2020)
Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis
Stephen Hanauer et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Real-World Experience with Tofacitinib in IBD at a Tertiary Center
Roni Weisshof et al.
DIGESTIVE DISEASES AND SCIENCES (2019)
DOP43 Long-term efficacy of tofacitinib in patients who received extended induction therapy: results of the OCTAVE open study for tofacitinib delayed responders
D T Rubin et al.
Journal of Crohns & Colitis (2019)
Efficacy of tofacitinib treatment in ulcerative colitis
Julian Panes et al.
GASTROENTEROLOGIA Y HEPATOLOGIA (2019)
Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme
William J. Sandborn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials
William J. Sandborn et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data
Fumi Varyani et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2019)
Acute severe ulcerative colitis: State of the art treatment
Javier P. Gisbert et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2018)
Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry
Maria Chaparro et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation
Carlos Taxonera et al.
DIGESTIVE DISEASES AND SCIENCES (2017)
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
Marcus Harbord et al.
JOURNAL OF CROHNS & COLITIS (2017)
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
Cong Dai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Maintenance therapy options for ulcerative colitis
Maria Chaparro et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response
Lior Katz et al.
INFLAMMATORY BOWEL DISEASES (2012)
Long-term durability of response to adalimumab in Crohn's disease
M. Chaparro et al.
INFLAMMATORY BOWEL DISEASES (2012)
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Long-term Durability of Infliximab Treatment in Crohn's Disease and Efficacy of Dose Escalation in Patients Losing Response
Maria Chaparro et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2011)
Use of the Noninvasive Components of the Mayo Score to Assess Clinical Response in Ulcerative Colitis
James D. Lewis et al.
INFLAMMATORY BOWEL DISEASES (2008)
Share Paper
